Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

University of Toronto

$265,030.00

Development of a physiological cardiac microtissue platform for drug development

EF 2018-19

Résumé
Poor efficacy and unpredictable toxic effects of drugs on the heart are leading causes of*removal of a drug from the market. Many drugs act unpredictably in patients because they are*tested in labs using cells grown in plastic dishes and in animals that poorly mimic humans.*Improved heart tissue models could identify and eliminate toxic and ineffective drugs earlier in*the drug discovery process.*To meet this need, we have developed a microfluidic platform that can model features of*tissues in the body, like blood flow and three-dimensional tissue arrangement, better than can*be done with standard cell culture models. This platform will be adapted to stretch and*electrically stimulate heart microtissues to better simulate human heart physiology. We have*also developed a new ultrasound imaging technique that can rapidly assess heart microtissue*beating and contraction from outside the platform. We propose to combine these techniques*to develop a new and improved heart model to rapidly and easily assess the function of heart*microtissues. This model will be unique in its compatibility with standard laboratory equipment*and medium- to high-throughput workflow, ensuring ease of implementation with minimal time*and effort.*We will optimize the new heart model to achieve functionality more similar to native human*heart tissue than currently possible, using patient-derived heart cells to model normal and*diseased heart tissue. At project completion, we will deliver a new best-in-class model of*human heart tissue that is expected to decrease the time and cost associated with drug*development by identifying ineffective and toxic drugs much earlier in the drug development*process than is possible with current methods.*This project will produce technologies that are primed for commercialization by our partner*companies and trainees with interdisciplinary expertise to lead the next generation of*innovations in the Canadian biotechnology, biomedicine, and health sectors.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
508366-2017
Name nom
Simmons, Craig
Department département
Mechanical and Industrial Engineering
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2017
Award amount
265030
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2
Nb partie
3
Application title
Development of a physiological cardiac microtissue platform for drug development
Keyword
NSERC
Application summary
Poor efficacy and unpredictable toxic effects of drugs on the heart are leading causes of*removal of a drug from the market. Many drugs act unpredictably in patients because they are*tested in labs using cells grown in plastic dishes and in animals that poorly mimic humans.*Improved heart tissue models could identify and eliminate toxic and ineffective drugs earlier in*the drug discovery process.*To meet this need, we have developed a microfluidic platform that can model features of*tissues in the body, like blood flow and three-dimensional tissue arrangement, better than can*be done with standard cell culture models. This platform will be adapted to stretch and*electrically stimulate heart microtissues to better simulate human heart physiology. We have*also developed a new ultrasound imaging technique that can rapidly assess heart microtissue*beating and contraction from outside the platform. We propose to combine these techniques*to develop a new and improved heart model to rapidly and easily assess the function of heart*microtissues. This model will be unique in its compatibility with standard laboratory equipment*and medium- to high-throughput workflow, ensuring ease of implementation with minimal time*and effort.*We will optimize the new heart model to achieve functionality more similar to native human*heart tissue than currently possible, using patient-derived heart cells to model normal and*diseased heart tissue. At project completion, we will deliver a new best-in-class model of*human heart tissue that is expected to decrease the time and cost associated with drug*development by identifying ineffective and toxic drugs much earlier in the drug development*process than is possible with current methods.*This project will produce technologies that are primed for commercialization by our partner*companies and trainees with interdisciplinary expertise to lead the next generation of*innovations in the Canadian biotechnology, biomedicine, and health sectors.